Just before the November 4th AMDAC on solithromycin, we are being treated to a very fine piece of study write-up. Of course, we are speaking of the File paper on the SOLITAIRE-IV trial, and what a fine piece of crafty
Continue reading Solithromycin SOLITAIRE-IV: So-So Results for a So-So Drug → Like this: Like Loading...
Posted in QIDP Antibiotics, Recent Literature, The News, The Viewpoint |
Tagged AIDAC, AMDAC, antibiotic blog, Avelox, CABP Guidance, Cempra, delta, drotrecogin, efficacy criteria, efficacy margins, FDA, FDA vs EU guidelines, File, Harald Reinhart, IV site reactions, IV/PO, ketolide, loading dose, macrolide, moxifloxacin, NI, non-inferiority, PORT score, SOLITAIRE-IV, SOLITAIRE-ORAL, tigecycline, Tygacil, Xigris |
SIRS, sepsis, severe sepsis, septic shock is a continuum, a crescendo of signs and symptoms associated with an infection uncontrolled by host responses. An avalanche or cascade of seemingly unstoppable events occurs often in a matter of hours which has
Continue reading Recent Sepsis Literature → Like this: Like Loading...
Posted in Recent Literature, The News, The Viewpoint |
Tagged afelimomab, Allphase Pharma Consulting, anti-IL-1, anti-PAF, anti-TNF mAb, antibiotic blog, Bayer, Bone criteria, Centocor, Chiron, drotrecogin, E5, Eisai, endotoxin, HA-1A, Harald Reinhart, ICU mortality, Ipsen, MAP 195, Novartis, Roche, sepsis, sepsis syndrome, septic shock, severe sepsis, SIRS, SIRS criteria, steroids, Synergen, TFPI, Tifacogin, Xigris, Xoma |
It is no secret that most existing antibiotic guidelines are not getting much use these days. The only indications pursued with any regularity are the feasible ones: ABSSSI, cUTI, and cIAI, much less CABP. Yes, the occasional HABP/VABP trial is
Continue reading Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!) → Like this: Like Loading...
Posted in Did you know...?, The News, The Viewpoint |
Tagged ABECB, ABECS, ABSSSI, AECB, Allphase Pharma Consulting, anti-infective indications, antibiotic blog, Avycaz, bacteremia, bacterial bronchitis, bacterial otitis media, bacterial sinusitis, ceftaroline, Ceftazidime/avibactam, ceftolozane/tazobactam, cIAI, Cubicin, Cubist, cUTI, daptomycin, drotrecogin, endocarditis, FDA, Francis Tally, HABP, Levaquin, levofloxacin, MDR pathogen trials, meningitis, MRSA, nosocomial pneumonia, osteomyelitis, prosthetic joint infection, S. aureus, sepsis, Sivextro, tedizolid, Teflaro, TFPI, thrombomodulin, Tifacogin, VABP, Xigris, Zerbaxa |
There is hardly an indication which has accumulated more failed clinical trials than the sepsis area. Called first bacteremia, later sepsis, sepsis syndrome or septic shock, there have been numerous attempts to influence the cascade of events that eventually lead
Continue reading Two New Approaches For Dealing with Sepsis / Toxemia → Like this: Like Loading...
Posted in Recent Literature, The Viewpoint |
Tagged antibiotic blog, bacteremia, bacterial dialysis, bacterial trapping, Bayer, dialysis, drotrecogin, E5 mAb, Eisai, endotoxin, Eritoran, HA1A, Lilly, liposomes, LPS, mannose-binding protein, MBP, MSOF, multi-system organ failure, nanoparticles, Roger Bone, sepsis, sepsis syndrome, septic shock, steroids, TFPI, Tifacogin, TNF-alpha inhibitor, toxemia, toxin binding, Xigris |